WEKO3
アイテム
{"_buckets": {"deposit": "8b912532-b2d3-47a1-8d16-f98c4b2f7cb7"}, "_deposit": {"created_by": 1, "id": "46608", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "46608"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00046608", "sets": ["1"]}, "author_link": ["464622", "464626", "464624", "464628", "464623", "464627", "464629", "464625"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "278", "bibliographicPageStart": "273", "bibliographicVolumeNumber": "18", "bibliographic_titles": [{"bibliographic_title": "International Journal of Clinical Oncology"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "BACKGROUND: The purpose of this phase I trial of S-1 chemotherapy in combination with pelvic radiotherapy for locally recurrent rectal cancer was to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose-limiting toxicity (DLT) of S-1.\n\\nMETHODS: We enrolled 9 patients between April 2005 and March 2009. Radiotherapy (total dose, 60 Gy in 30 fractions) was given to the gross local recurrent tumor and pelvic nodal metastases using three-dimensional radiotherapy planning. We administered oral S-1 twice a day on days 1-14 and 22-35 during radiotherapy. The dose of S-1 was initially 60 mg/m(2)/day and was increased to determine the MTD and RD for this regimen.\n\\nRESULTS: DLT appeared at dose level 2 (70 mg/m(2)/day) in 2 patients, who experienced grade 3 enterocolitis and consequently required suspension of S-1 administration for longer than 2 weeks. Hematological toxicity was mild and reversible. At the initial evaluation, complete regression and partial regression were seen in 1 patient (11%) and 2 patients (22%), respectively.\n\\nCONCLUSION: This phase I trial of S-1 chemotherapy with pelvic radiotherapy for locally recurrent rectal cancer revealed that the MTD for S-1 was 70 mg/m(2)/day and the RD was 60 mg/m(2)/day.", "subitem_description_type": "Abstract"}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s10147-012-0375-y", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Wada, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "464622", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nemoto, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "464623", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nomiya, Takuma"}], "nameIdentifiers": [{"nameIdentifier": "464624", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murakami, Misako"}], "nameIdentifiers": [{"nameIdentifier": "464625", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Motohisa"}], "nameIdentifiers": [{"nameIdentifier": "464626", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "et.al"}], "nameIdentifiers": [{"nameIdentifier": "464627", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "野宮 琢磨", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "464628", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鈴木 志恒", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "464629", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer."}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/46608", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-10-17"}, "publish_date": "2013-10-17", "publish_status": "0", "recid": "46608", "relation": {}, "relation_version_is_last": true, "title": ["A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer."], "weko_shared_id": -1}
A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer.
https://repo.qst.go.jp/records/46608
https://repo.qst.go.jp/records/466080a1abe73-103b-4228-9ff9-20956645df79
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-10-17 | |||||
タイトル | ||||||
タイトル | A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Wada, Hitoshi
× Wada, Hitoshi× Nemoto, Kenji× Nomiya, Takuma× Murakami, Misako× Suzuki, Motohisa× et.al× 野宮 琢磨× 鈴木 志恒 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | BACKGROUND: The purpose of this phase I trial of S-1 chemotherapy in combination with pelvic radiotherapy for locally recurrent rectal cancer was to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose-limiting toxicity (DLT) of S-1. \nMETHODS: We enrolled 9 patients between April 2005 and March 2009. Radiotherapy (total dose, 60 Gy in 30 fractions) was given to the gross local recurrent tumor and pelvic nodal metastases using three-dimensional radiotherapy planning. We administered oral S-1 twice a day on days 1-14 and 22-35 during radiotherapy. The dose of S-1 was initially 60 mg/m(2)/day and was increased to determine the MTD and RD for this regimen. \nRESULTS: DLT appeared at dose level 2 (70 mg/m(2)/day) in 2 patients, who experienced grade 3 enterocolitis and consequently required suspension of S-1 administration for longer than 2 weeks. Hematological toxicity was mild and reversible. At the initial evaluation, complete regression and partial regression were seen in 1 patient (11%) and 2 patients (22%), respectively. \nCONCLUSION: This phase I trial of S-1 chemotherapy with pelvic radiotherapy for locally recurrent rectal cancer revealed that the MTD for S-1 was 70 mg/m(2)/day and the RD was 60 mg/m(2)/day. |
|||||
書誌情報 |
International Journal of Clinical Oncology 巻 18, 号 2, p. 273-278, 発行日 2012-02 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1341-9625 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s10147-012-0375-y |